Birchview Capital
Latest statistics and disclosures from Birchview Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BMY, NBIX, BDSX, PRTA, ACAD, and represent 61.28% of Birchview Capital's stock portfolio.
- Added to shares of these 10 stocks: AXGN, PRTA, BLUE, KPTI, TVTX, TXG, SILK, PGNY, BDSX, APLS.
- Reduced shares in these 8 stocks: Accelr8 Technology (-$12M), Soleno Therapeutics, Iveric Bio, UTHR, NBIX, BMY, Chinook Therapeutics, ACAD.
- Sold out of its positions in Chinook Therapeutics, Iveric Bio, Soleno Therapeutics.
- Birchview Capital was a net seller of stock by $-12M.
- Birchview Capital has $118M in assets under management (AUM), dropping by -11.90%.
- Central Index Key (CIK): 0001618205
Tip: Access up to 7 years of quarterly data
Positions held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Birchview Capital
Birchview Capital holds 51 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | 35.4 | $42M | 716k | 58.04 |
|
|
| Neurocrine Biosciences (NBIX) | 7.4 | $8.7M | -8% | 77k | 112.50 |
|
| Biodesix (BDSX) | 7.3 | $8.6M | +3% | 5.2M | 1.65 |
|
| Prothena Corp SHS (PRTA) | 7.0 | $8.2M | +8% | 170k | 48.25 |
|
| ACADIA Pharmaceuticals (ACAD) | 4.3 | $5.0M | -3% | 240k | 20.84 |
|
| Quidel Corporation | 4.1 | $4.8M | 65k | 73.04 |
|
|
| Encana Corporation (OVV) | 3.4 | $4.0M | 84k | 47.57 |
|
|
| ImmunoGen | 2.6 | $3.0M | 190k | 15.87 |
|
|
| United Therapeutics Corporation (UTHR) | 2.1 | $2.5M | -26% | 11k | 225.87 |
|
| Aziyo Biologics (ELUT) | 2.0 | $2.4M | 1.7M | 1.43 |
|
|
| Harrow Health (HROW) | 1.8 | $2.2M | 150k | 14.37 |
|
|
| Phreesia (PHR) | 1.3 | $1.5M | 83k | 18.68 |
|
|
| Alkermes SHS (ALKS) | 1.2 | $1.4M | 50k | 28.01 |
|
|
| Bluebird Bio (BLUE) | 1.2 | $1.4M | +82% | 455k | 3.04 |
|
| Corcept Therapeutics Incorporated (CORT) | 1.2 | $1.4M | 50k | 27.25 |
|
|
| Masimo Corporation (MASI) | 1.1 | $1.3M | 15k | 87.68 |
|
|
| Foghorn Therapeutics (FHTX) | 1.1 | $1.3M | 265k | 5.00 |
|
|
| Accelr8 Technology | 1.1 | $1.3M | -89% | 225k | 5.75 |
|
| Inhibrx (INBX) | 1.1 | $1.3M | 70k | 18.35 |
|
|
| Equitrans Midstream Corp (ETRN) | 1.1 | $1.2M | 133k | 9.37 |
|
|
| Alphatec Holdings (ATEC) | 0.9 | $1.0M | 80k | 12.97 |
|
|
| Ventyx Biosciences (VTYX) | 0.8 | $917k | 26k | 34.73 |
|
|
| Pioneer Natural Resources (PXD) | 0.7 | $872k | 3.8k | 229.55 |
|
|
| 10x Genomics Cl A Com (TXG) | 0.7 | $866k | +75% | 21k | 41.25 |
|
| Axogen (AXGN) | 0.7 | $865k | +332% | 173k | 5.00 |
|
| Karyopharm Therapeutics (KPTI) | 0.7 | $766k | +96% | 572k | 1.34 |
|
| Cytokinetics (CYTK) | 0.6 | $737k | 25k | 29.46 |
|
|
| Travere Therapeutics (TVTX) | 0.6 | $733k | +105% | 82k | 8.94 |
|
| Docgo (DCGO) | 0.6 | $693k | +18% | 130k | 5.33 |
|
| Apellis Pharmaceuticals (APLS) | 0.6 | $685k | +50% | 18k | 38.04 |
|
| Protagonist Therapeutics (PTGX) | 0.5 | $634k | 38k | 16.68 |
|
|
| Silk Road Medical Inc Common (SILK) | 0.5 | $619k | +106% | 41k | 14.99 |
|
| Progyny (PGNY) | 0.5 | $612k | +100% | 18k | 34.02 |
|
| Kiniksa Pharmaceuticals (KNSA) | 0.4 | $521k | 30k | 17.37 |
|
|
| Kalvista Pharmaceuticals (KALV) | 0.3 | $385k | 40k | 9.63 |
|
|
| Halozyme Therapeutics (HALO) | 0.3 | $382k | 10k | 38.20 |
|
|
| Xenon Pharmaceuticals (XENE) | 0.3 | $342k | 10k | 34.16 |
|
|
| Amicus Therapeutics (FOLD) | 0.3 | $341k | 28k | 12.16 |
|
|
| Stoke Therapeutics (STOK) | 0.3 | $335k | 85k | 3.94 |
|
|
| Sarepta Therapeutics (SRPT) | 0.3 | $303k | 2.5k | 121.22 |
|
|
| Arvinas Ord (ARVN) | 0.3 | $295k | 15k | 19.64 |
|
|
| Xencor (XNCR) | 0.2 | $248k | 12k | 20.15 |
|
|
| 2seventy Bio (TSVT) | 0.2 | $235k | 60k | 3.92 |
|
|
| Cullinan Oncology (CGEM) | 0.2 | $227k | 25k | 9.05 |
|
|
| Keros Therapeutics (KROS) | 0.2 | $223k | 7.0k | 31.88 |
|
|
| Gossamer Bio (GOSS) | 0.1 | $174k | +111% | 209k | 0.83 |
|
| G1 Therapeutics (GTHX) | 0.1 | $173k | +200% | 120k | 1.44 |
|
| Inflarx Nv (IFRX) | 0.1 | $149k | 50k | 2.98 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 0.1 | $142k | 20k | 7.08 |
|
|
| Nektar Therapeutics (NKTR) | 0.0 | $17k | 28k | 0.60 |
|
|
| Yield10 Bioscience | 0.0 | $6.1k | 19k | 0.33 |
|
Past Filings by Birchview Capital
SEC 13F filings are viewable for Birchview Capital going back to 2014
- Birchview Capital 2023 Q3 filed Nov. 14, 2023
- Birchview Capital 2023 Q2 filed Aug. 8, 2023
- Birchview Capital 2023 Q1 filed May 12, 2023
- Birchview Capital 2022 Q4 filed Feb. 3, 2023
- Birchview Capital 2022 Q3 restated filed Nov. 28, 2022
- Birchview Capital 2022 Q3 filed Nov. 7, 2022
- Birchview Capital 2022 Q2 filed Aug. 12, 2022
- Birchview Capital 2022 Q1 filed May 13, 2022
- Birchview Capital 2021 Q4 filed Feb. 14, 2022
- Birchview Capital 2021 Q3 filed Nov. 12, 2021
- Birchview Capital 2021 Q2 filed Aug. 10, 2021
- Birchview Capital 2021 Q1 filed May 14, 2021
- Birchview Capital 2020 Q4 filed Feb. 9, 2021
- Birchview Capital 2020 Q3 restated filed Nov. 12, 2020
- Birchview Capital 2020 Q3 filed Nov. 12, 2020
- Birchview Capital 2020 Q2 restated filed Sept. 25, 2020